Top

18-11-2024 | Breast Cancer | Original Article

Real-world incidence of and risk factors for abemaciclib-induced interstitial lung disease in Japan: a nested case–control study of abemaciclib-induced interstitial lung disease (NOSIDE)

Authors: Sayuka Nakayama, Ayuha Yoshizawa, Junji Tsurutani, Kenichi Yoshimura, Gaku Aoki, Takayuki Iwamoto, Hiroyuki Nagase, Naoya Sugimoto, Konomi Kobayashi, Shinyu Izumi, Terufumi Kato, Yasunari Miyazaki, Yasuyuki Kurihara, Naruto Taira, Tomohiko Aihara, Yuichiro Kikawa, Hirofumi Mukai

Published in: Breast Cancer

Abstract

Purpose

The exact incidence of and risk factors for interstitial lung disease (ILD), a serious side effect of abemaciclib, remain unknown in real-world settings. We examined the incidence of and risk factors for abemaciclib-induced ILD in patients with advanced breast cancer (ABC) in Japan.

Patients and Methods

Retrospective clinical information was collected from charts of patients with ABC who had started abemaciclib treatment at 77 participating institutions between November 30, 2018 and December 31, 2019. The clinical information of patients who developed ILD (including suspected cases) were reviewed by an independent committee of extramural experts to adjudicate abemaciclib-induced ILD. We performed a nested case–control study for efficient identification of ILD risk factors and conducted multivariate Cox regression analysis to identify independent predictors of ILD.

Results

Among patients taking abemaciclib, the incidence of abemaciclib-induced ILD was 5.0% (n = 59/1189), and the mortality rate was 0.7% (n = 8). The timing of ILD onset varied but occurred most frequently within 180 days of beginning abemaciclib treatment (64.4%). The incidence of abemaciclib-induced ILD was significantly associated with Eastern Cooperative Oncology Group performance status (ECOG PS) ≥ 2 [hazard ratio (HR) 5.03; 95% confidence interval (CI) 2.26–11.11] or a past medical history of interstitial pneumonia (IP) (HR 6.49; 95% CI 3.09–13.70).

Conclusions

In this study, we have for the first time determined the real-world incidence of and risk factors for abemaciclib-induced ILD in Japan. Although abemaciclib-induced ILD is serious in real-world settings, careful patient selection and close monitoring of those with poor ECOG PS and/or a history of IP may minimize ILD risk.

This study was registered on the UMIN registry (Date: May 11, 2020/ ID: UMIN000040357).

Available only for authorised users

Lobbezoo DJ, van Kampen RJ, Voogd AC, et al. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat. 2013;141(3):507–14. https://doi.org/10.1007/s10549-013-2711-y.CrossRefPubMed

Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–49. https://doi.org/10.1016/j.annonc.2020.09.010.CrossRefPubMed

Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–39. https://doi.org/10.1016/s1470-2045(15)00613-0.CrossRefPubMed

Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–48. https://doi.org/10.1056/NEJMoa1609709.CrossRefPubMed

Torres-Guzmán R, Calsina B, Hermoso A, et al. Preclinical characterization of abemaciclib in hormone receptor positive breast cancer. Oncotarget. 2017;8(41):69493–507. https://doi.org/10.18632/oncotarget.17778.CrossRefPubMedPubMedCentral

Lallena MJ, Boehnke K, Torres R, et al. Abstract 3101: in-vitro characterization of Abemaciclib pharmacology in ER+ breast cancer cell lines. Cancer Res. 2015;75(15):3101–3101. https://doi.org/10.1158/1538-7445.Am2015-3101.CrossRef

Torres-Guzmán R, Ganado MP, Mur C, et al. Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation. Oncotarget. 2022;13:864–75. https://doi.org/10.18632/oncotarget.28249.CrossRefPubMedPubMedCentral

Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, A Phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)/HER2(−) metastatic breast cancer. Clin Cancer Res. 2017;23(17):5218–24. https://doi.org/10.1158/1078-0432.Ccr-17-0754.CrossRefPubMedPubMedCentral

Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–84. https://doi.org/10.1200/jco.2017.73.7585.CrossRefPubMed

10.

Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–46. https://doi.org/10.1200/jco.2017.75.6155.CrossRefPubMed

11.

Toi M, Inoue K, Masuda N, et al. Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials. Cancer Sci. 2021;112(6):2381–92. https://doi.org/10.1111/cas.14877.CrossRefPubMedPubMedCentral

12.

Chen Y, Noma S, Taguchi Y, et al. Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan. Breast Cancer. 2021;28(3):710–9. https://doi.org/10.1007/s12282-020-01207-8.CrossRefPubMed

13.

Inoue K, Masuda N, Iwata H, et al. Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. Breast Cancer. 2021;28(5):1038–50. https://doi.org/10.1007/s12282-021-01239-8.CrossRefPubMed

14.

Takahashi M, Tokunaga E, Mori J, et al. Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Breast Cancer. 2022;29(1):174–84. https://doi.org/10.1007/s12282-021-01295-0.CrossRefPubMed

15.

Samuelsen SO. A psudolikelihood approach to analysis of nested case-control studies. Biometrika. 1997;84(2):379–94. https://doi.org/10.1093/biomet/84.2.379.CrossRef

16.

Scagnoli S, Pisegna S, Toss A, et al. Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study. NPJ Breast Cancer. 2024;10(1):58. https://doi.org/10.1038/s41523-024-00657-z.CrossRefPubMedPubMedCentral

17.

Lin W, Zeng Y, Weng L, Yang J, Zhuang W. Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA’s adverse event reporting system: a case control pharmacovigilance study. BMC Pharmacol Toxicol. 2024;25(1):47. https://doi.org/10.1186/s40360-024-00770-6.CrossRefPubMedPubMedCentral

18.

Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364(16):1503–12. https://doi.org/10.1056/NEJMoa1013660.CrossRefPubMedPubMedCentral

19.

Swigris JJ, Olson AL, Huie TJ, et al. Ethnic and racial differences in the presence of idiopathic pulmonary fibrosis at death. Respir Med. 2012;106(4):588–93. https://doi.org/10.1016/j.rmed.2012.01.002.CrossRefPubMedPubMedCentral

20.

Kubo K, Azuma A, Kanazawa M, et al. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig. 2013;51(4):260–77. https://doi.org/10.1016/j.resinv.2013.09.001.CrossRefPubMed

21.

Iwasa E, Fujiyoshi Y, Kubota Y, et al. Interstitial lung disease as an adverse drug reaction in Japan: exploration of regulatory actions as a basis for high reporting. Drug Saf. 2020;43(11):1121–31. https://doi.org/10.1007/s40264-020-00968-7.CrossRefPubMedPubMedCentral

22.

Ushiki A, Hanaoka M. Clinical characteristics of DLI: what are the clinical features of DLI? In: Hanaoka M, Nakamura H, Aoshiba K, editors. Drug-induced lung injury. Springer: Singapore; 2018. p. 27–33.CrossRef

23.

Komada F, Nakayama Y, Takara K. Analysis of time-to-onset and onset-pattern of interstitial lung disease after the administration of monoclonal antibody agents. Yakugaku Zasshi. 2018;138(12):1587–94. https://doi.org/10.1248/yakushi.18-00094.CrossRefPubMed

24.

Matsumoto K, Nakao S, Hasegawa S, et al. Analysis of drug-induced interstitial lung disease using the Japanese adverse drug event report database. SAGE Open Med. 2020;8:2050312120918264. https://doi.org/10.1177/2050312120918264.CrossRefPubMedPubMedCentral

25.

Osawa M, Kudoh S, Sakai F, et al. Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study. Int J Clin Oncol. 2015;20(6):1063–71. https://doi.org/10.1007/s10147-015-0834-3.CrossRefPubMedPubMedCentral

26.

Conte P, Ascierto PA, Patelli G, et al. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open. 2022;7(2):100404. https://doi.org/10.1016/j.esmoop.2022.100404.CrossRefPubMedPubMedCentral

27.

Furuse J, Gemma A, Ichikawa W, Okusaka T, Seki A, Ishii T. Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis. Jpn J Clin Oncol. 2017;47(9):832–9. https://doi.org/10.1093/jjco/hyx075.CrossRefPubMedPubMedCentral

28.

Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987–98. https://doi.org/10.1200/jco.20.02514.CrossRefPubMedPubMedCentral

29.

Gemma A, Kudoh S, Ando M, et al. Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer. Cancer Sci. 2014;105(12):1584–90. https://doi.org/10.1111/cas.12550.CrossRefPubMedPubMedCentral

30.

Nakano K, Seto A, Sasaki T, et al. Incidence and risk factors of interstitial lung disease of patients with head and neck cancer treated with cetuximab. Head Neck. 2019;41(8):2574–80. https://doi.org/10.1002/hed.25727.CrossRefPubMed

31.

Kudoh S, Kato H, Nishiwaki Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med. 2008;177(12):1348–57. https://doi.org/10.1164/rccm.200710-1501OC.CrossRefPubMed

Title: Real-world incidence of and risk factors for abemaciclib-induced interstitial lung disease in Japan: a nested case–control study of abemaciclib-induced interstitial lung disease (NOSIDE)
Authors: Sayuka Nakayama
Ayuha Yoshizawa
Junji Tsurutani
Kenichi Yoshimura
Gaku Aoki
Takayuki Iwamoto
Hiroyuki Nagase
Naoya Sugimoto
Konomi Kobayashi
Shinyu Izumi
Terufumi Kato
Yasunari Miyazaki
Yasuyuki Kurihara
Naruto Taira
Tomohiko Aihara
Yuichiro Kikawa
Hirofumi Mukai
Publication date: 18-11-2024
Publisher: Springer Nature Singapore
Keywords: Breast Cancer
Breast Cancer
Published in: Breast Cancer
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-024-01648-5

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Targeted Therapy
On-demand webinar

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Keynote series | Spotlight on menopause

Springer Medicine

Real-world incidence of and risk factors for abemaciclib-induced interstitial lung disease in Japan: a nested case–control study of abemaciclib-induced interstitial lung disease (NOSIDE)

Abstract

Purpose

Patients and Methods

Results

Conclusions

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Purpose

Patients and Methods

Results

Conclusions

Please log in to get access to this content

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma